how much is considered a microdose of semaglutide Microdosing chart: The complete guide People are 'microdosing' weight-loss drugs.

We already know that GLP-1s act on the brain in various ways

10 / 2026 Zealand Pharma announces Boehringer Ingelheim's novel glucagon/GLP-1 dual agonist survodutide achieved significant weight loss of 16.6% delivering meaningful metabolic improvement in people living with obesity or overweight in Phase 3 trial In SYNCHRONIZE-1, participants lost up to an average of 39.2 lb (17.8 kg) from baseline after 76 weeks of treatment with survodutide, a glucagon/GLP-1 receptor dual agonist1 The trial met both weight loss primary endpoints and its key secondary endpoint evaluating waist circumference, a predictor of cardiometabolic risk, together demonstrating survodutide's potential to broadly improve metabolic health1 In addition to these positive results, Boehringer is advancing its broad metabolic health R&D program, exploring multiple pharmaceutical approaches to weight management including oral treatments

Our patients rate our online doctor service as excellent on Trustpilot

Contains antioxidants and tone-evening ingredients glutathione, vitamin C, niacinamide and tranexamic acid to help gently yet effectively fade hyperpigmentation and darks spots and even out dull, uneven skin tone